S17 Ep42: Treatment Intensification in Vulnerable Populations: ARPI Use in Elderly, Frail, and High-Comorbidity Patients With mCSPC: With Martin Schoen, MD, and Andrew W. Hahn, MD

In today’s episode, we spoke with Martin Schoen, MD, and Andrew W. Hahn, MD. Dr Schoen is a hematologist/oncologist and hospitalist at St. Louis Veterans Affairs Medical Center and Assistant Professor of Medicine at Saint Louis University. Hahn is an assistant professor in the Department of Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer Center.

In our exclusive interview, Drs Schoen and Hahn discussed the clinical evidence for androgen receptor pathway inhibitors (ARPIs), including enzalutamide, in patients with de novo metastatic castration-sensitive prostate cancer (mCSPC) who are elderly, frail, or have a high comorbidity burden. They also highlighted findings from a subgroup analysis the Veterans Affairs dataset evaluating outcomes with androgen deprivation therapy plus ARPIs in high-comorbidity, frail, and elderly patients with high-volume mCSPC.